This is the second one fourth of the nine-month period ending Dec.

Net interest expenditure was $3.2 million, in comparison to net interest expense of $22.4 million for the same period in the prior year. The decrease was driven by the successful refinancing and repricing of the organization's term loans completed in 2012 and 2013, respectively. Stability Sheet At Sept. 30, 2013, Alkermes recorded money and total investments of $395.2 million, in comparison to $ June 30 0 million, 2013, and $304.2 million at March 31, 2013. Financial Expectations for Nine Months Ending Dec. 31, 2013 The ongoing company reiterated most of its financial goals for the nine-month period ending Dec. 31, 2013, provided on, may 23 except for Selling, General and Administrative expense, which the company today expects to be in the range of $105 million to $115 million, up from the previous range of $95 million to $105 million, reflecting increased industrial activity in preparation for the aripiprazole lauroxil start and activities linked to the VIVITROL label revise.All proceeds were received in the second quarter aside from $ July 2011 7 million which was received. In April 2011, the Company entered into definitive agreements with traders for a private keeping up to $4.5 million in convertible notes. The original closing on, may 2, 2011 provided funding of around $1.3 million, net of most transaction costs. The traders have the right to purchase up to $3.0 million of extra notes through May 2013. In 2011 June, the Company entered into definitive agreements for a $24.0 million private placement of common stock and warrants.